从以人为中心的角度对药丸和药物分配器进行系统审查
Luigi Gargioni1, Daniela Fogli1, Pietro Baroni1
1Department of Information Engineering, University of Brescia, Via Branze 38, Brescia, 25123 Italy.
Journal of healthcare informatics research
|April 29, 2024
概括
药丸和药物分发器可以改善患者对治疗的坚持. 本系统性审查分析了当前的配剂器解决方案,用户界面和管理,为未来的开发和医疗保健专业人员提供了洞察力.
科学领域:
- 医疗信息学 医疗信息学
- 人与计算机的交互
- 医疗器械技术 医疗器械技术
背景情况:
- 药物坚持是影响患者结果的重大医疗保健挑战.
- 药丸和药物分发器正在成为增强坚持药物的技术解决方案.
- 用户接受对于这些配剂器的成功实施至关重要.
研究的目的:
- 系统地审查现有的药丸和药物分配器解决方案.
- 从以人为中心的角度分析配剂器解决方案,专注于用户接受.
- 为未来药物配送器技术的研发提供见解.
主要方法:
- 按照PRISMA (系统审查和元分析的首选报告项目) 准则进行系统的文献审查.
- 在Scopus和PubMed数据库中进行的搜索.
- 基于开发阶段,硬件/软件架构,用户界面特性和用户参与度的配剂器解决方案分析.
主要成果:
- 根据发展阶段对当前的药丸和药物分配器解决方案的概述和分类.
- 详细分析各种配剂器类型的硬件/软件架构.
- 审查用户界面设计和在配剂器管理中的用户角色.
结论:
- 了解配剂器技术,用户界面和管理是有效实施的关键.
- 未来的研究应该专注于以人为中心的设计,以最大限度地提高用户的接受和坚持.
- 提供的洞察力可以指导医疗保健专业人员,研究人员和设计人员开发和使用药物分发器.
相关概念视频
Dosage Regimens: Designs and Approaches
600
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
600
Drug Dosing: Geriatric Patients
395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
Modified-Release Drug Delivery Systems: Overview
236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Oral Drug Delivery Systems: Introduction
279
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
279
Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308


